QualityDipStocks / Health Care · Medical Specialities
The Cigna Group CI
Not in a dip by our rules: 6% below its 52-week high.
A quality company, 6% over its Market Value. No fair value estimate for now: the model’s result is too extreme to stand behind.
- Fair value est.
- n/a
- Market Value
- $281.64price +6%
- Off 52-wk high
- −6%
- Risk vs market
- Lowbeta 0.12
5 bullish · 4 bearish See why
Key levels
Every level vs today’s $298.23
- 52-wk lowlowest close, 1 year$244.41−18.0%
- Market Valueavg paid since Jul 30$281.64−5.6%
- PriceFri Oct 30 close$298.23you are here
- 52-wk highhighest close, 1 year$315.88+5.9%
Fair value estimate
Estimate unreliable for CI: the model gives 257% above the price, more than we can stand behind (usually peak-cycle cash flow, heavy debt, or cash flows that include customer or loan balances). We’d rather show nothing than a made-up number.
What the price implies To be worth today’s price, CI’s free cash flow would need to shrink about 8% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much CI moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 2.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.12
- Volatility
- 33% vs 13% SPY
- Correlation SPY
- 0.05
- Correlation QQQ
- −0.09
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthDiluted EPS grew 83% to $22.18 in FY2025.
ValuationP/E of 12.3× is 30% below its own average of 17.5× at the last 3 fiscal year-ends.
ValuationP/E of 12.3× vs a 29.2× median for the 86 Health Care companies we cover.
GrowthSales compounded 15% a year from FY2022 to FY2025.
QualityPasses all four of our quality checks: cash generation, returns on capital, growth and balance sheet.
Top bearish points 4 of 5
ProfitabilityGross margin narrowed to 21.8% in FY2025 from 31.5% in FY2023 (SEC filings).
ProfitabilityOperating margin of 3.5%, below the 13% median for the 89 Health Care companies we cover.
Balance sheetDebt / equity of 0.7×, above the 0.7× median for the 67 Health Care companies we cover.
ValuationTrades 5.9% above its Market Value of $281.64, the average price paid since the Jul 30 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on The Cigna Group in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical Specialities
All fundamentals
P/E 12.3 · ROE 15% · Sales +8%
Valuation
- P/E
- 12.3×3-yr-end avg 17.5× · Health Care median 29.2×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- 8.0×
- Price / sales
- 0.28×
- Price / book
- 1.85×
- Market cap
- $78.7Bprice × diluted shares
- Enterprise value
- $102B
Growth
- Revenue, 12 months
- $282B
- Sales growth, 12 months
- +7.8%vs the 12 months before
- Sales growth, 3 yrs
- +15.0%/yrfrom FY2022
- Diluted EPS, 12 months
- $24.18
- EPS growth, last FY
- +83.0%
- Net income, 12 months
- $6.4B
- Net income growth
- +28%12 months vs before
Profitability
- Gross margin
- 20.6%
- Operating margin
- 3.5%
- Net margin
- 2.3%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 15%
- Return on invested capital
- 12%
Balance sheet
- Cash & short-term inv.
- $7.3B
- Total debt
- $30.1B
- Net cash
- −$22.8B
- Debt / equity
- 0.71×
- Interest coverage
- 7.0×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 2.06%$1.6B paid
- Payout ratio
- 25%
- Buybacks, 12 months
- $1.3B1.6% of market cap
- Share count, 1 year
- −1.6%diluted shares vs a year ago
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From The Cigna Group’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
MV $281.64 · FCF value $860.86
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only arm once a company is in a dip.
Momentum & 52-week range
RSI 56 · 5 days −2.8%
The business
FCF $9.1B · Sales +7%
- Free cash flow, 12 months$9.1B
- Free-cash-flow yield11.5%
- Free-cash-flow margin3%
- Gross margin9%
- Operating margin3%
- Return on invested capital9%
- Return on equity15%
- Sales growth (latest quarter vs year-ago quarter)+7%
- Net debt / EBITDA2.0×
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS$7.46
- Year-ago EPS$7.83
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
Get a text when CI fires a reversal signal
One text when a published rule fires on CI or any of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.